Vonapanitase

Summary

Vonapanitase (CHEMBL3545070) is a phase-3 clinical-stage enzyme; indicated across 2 conditions including chronic kidney disease and peripheral arterial disease.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Enzyme
• Indications: 2 conditions
• Clinical trials: 8

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3545070
Name	Vonapanitase
Type	Enzyme
Max phase	3

Also known as: Pancreatic elastase 1, PRT-201, PRT201, Vonapanitasa, Vonapanitase, VONAPANITASE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
chronic kidney disease	3	MONDO:0005300	EFO:0003884
peripheral arterial disease	1	MONDO:0005386	EFO:0004265

Clinical trials

Total trials: 8.

Phase distribution

Phase	Trials
PHASE1	3
PHASE3	2
PHASE1/PHASE2	2
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02110901	PHASE3	COMPLETED	A Study of PRT-201 Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-1)
NCT02414841	PHASE3	COMPLETED	A Study of Vonapanitase (PRT-201) Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-2)
NCT00679991	PHASE1/PHASE2	COMPLETED	A Phase 1-2 Study of PRT-201 Administered in Chronic Kidney Disease (CKD) Patients
NCT01001351	PHASE1/PHASE2	COMPLETED	A Study of PRT-201 Administered After Arteriovenous Graft (AVG) Creation in Patients With Chronic Kidney Disease
NCT01305824	PHASE2	COMPLETED	A Study of PRT-201 Administered Immediately After Arteriovenous Fistula Creation in Patients With Chronic Kidney Disease
NCT01616290	PHASE1	COMPLETED	Pilot Study of PRT-201 Following Angioplasty in Patients With Peripheral Artery Disease (PAD)
NCT02953496	PHASE1	WITHDRAWN	Safety/ Feasibility of Percutaneous Administration of Vonapanitase as Monotherapy for Peripheral Artery Disease (PAD) of the SFA and Popliteal Arteries
NCT02956993	PHASE1	COMPLETED	Safety/Feasibility of Vonapanitase Following Angioplasty for Patients With Peripheral Artery Disease (PAD) Below the Knee (BTK)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).